Combating the West Nile virus through immunology
HIPRA is participating in a research project that aims to design therapies to limit the impact of the West Nile virus (WNV), an emerging pathogen for which there is currently no treatment or vaccine for use in humans. The project is coordinated by the IrsiCaixa AIDS Research Institute and has the participation of 6 partners from Spain, France and Denmark: Barcelona Supercomputing Center, Centre for Genomic Regulation, HIPRA Scientific S.L., Université de Montpellier, Technische Universität Braunschweig and Kloverpris Lab (University of Copenhagen).
All research centers will work on the development of a safe and effective prophylactic vaccine against WNV that is capable of inducing a prolonged immune response over time and protecting the entire population.
Within the same project, called LWNVIVAT (from the English Limiting West Nile Virus Impact by Novel Vaccines And Therapeutics Approaches), the scientific team will design, produce and analyze the efficacy and therapeutic potential of specific antibodies for the virus, apart from the vaccine.
